低分子肝素钠治疗难治性肾病综合征的临床疗效分析  

Analysis of clinical efficacy of low-molecular-weight heparin sodium in the treatment of refractory nephrotic syndrome

作　　者：李丹 LI Dan(Huludao Central Hospital,Huludao 125001,China)

机构地区：[1]葫芦岛市中心医院,125001

出　　处：《中国实用医药》2023年第8期123-125,共3页China Practical Medicine

摘　　要：目的探究低分子肝素钠治疗难治性肾病综合征的临床价值。方法88例难治性肾病综合征患者为研究对象,按照就诊的先后顺序分为实验组和对照组,各44例。对照组采用激素与环磷酰胺治疗,实验组在对照组基础上采用低分子肝素钠治疗。比较两组治疗效果、肾功能指标[血尿素氮(BUN)、血肌酐(Scr)、24 h尿蛋白、血清白蛋白(ALB)]、不良反应发生情况。结果实验组治疗总有效率93.18%显著高于对照组的77.27%,差异有统计学意义(P<0.05)。实验组BUN(3.36±2.13)mmol/L、Scr(92.47±12.34)μmol/L、24 h尿蛋白(2.06±1.12)g/L、ALB(37.26±6.53)g/L均显著优于对照组的(6.47±3.27)mmol/L、(115.89±13.22)μmol/L、(3.84±1.99)g/L、(29.11±6.13)g/L,差异有统计学意义(P<0.05)。实验组不良反应发生率为4.55%低于对照组的20.45%,差异有统计学意义(P<0.05)。结论难治性肾病综合征患者采用低分子肝素钠治疗,效果显著,可有效改善肾功能指标,安全性更高,值得在临床上广泛应用。Objective To investigate the clinical value of low-molecular weight heparin sodium in the treatment of refractory nephrotic syndrome.Methods A total of 88 patients with refractory nephrotic syndrome were studied and divided into experimental group and control group according to the order of treatment,with 44 cases in each group.The control group was treated with hormone and cyclophosphamide,and the experimental group was treated with low-molecular-weight heparin sodium based on the control group.Both groups were compared in terms of therapeutic effect,renal function indexes[blood urea nitrogen(BUN),serum creatinine(Scr),24 h urinary protein,serum albumin(ALB)],and the incidence of adverse reactions.Results The total effective rate of 93.18%in the experimental group was significantly higher than that of 77.27%in the control group,and the difference was statistically significant(P<0.05).The experimental group had BUN of(3.36±2.13)mmol/L,Scr of(92.47±12.34)μmol/L,24 h urinary protein of(2.06±1.12)g/L and ALB of(37.26±6.53)g/L,which were significantly better than those of(6.47±3.27)mmol/L,(115.89±13.22)μmol/L,(3.84±1.99)g/L and(29.11±6.13)g/L in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions of the experimental group was 4.55%,which was lower than that of 20.45%of the control group,and the difference was statistically significant(P<0.05).Conclusion Low-molecular-weight heparin sodium has a significant therapeutic effect for patients with refractory nephrotic syndrome,and can improve the renal function with high safety.It is worthy of clinical application.

关 键 词：低分子肝素钠 难治性肾病综合征 不良反应 

分 类 号：R692[医药卫生—泌尿科学]